Cargando…
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interac...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238480/ https://www.ncbi.nlm.nih.gov/pubmed/22184537 http://dx.doi.org/10.4081/hr.2011.e16 |
_version_ | 1782219007979421696 |
---|---|
author | Morales-Molina, José Antonio Martínez-de la Plata, Juan Enrique Urquízar-Rodríguez, Olivia Molina-Arrebola, María Angustias |
author_facet | Morales-Molina, José Antonio Martínez-de la Plata, Juan Enrique Urquízar-Rodríguez, Olivia Molina-Arrebola, María Angustias |
author_sort | Morales-Molina, José Antonio |
collection | PubMed |
description | Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0–3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time. |
format | Online Article Text |
id | pubmed-3238480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32384802011-12-19 Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far Morales-Molina, José Antonio Martínez-de la Plata, Juan Enrique Urquízar-Rodríguez, Olivia Molina-Arrebola, María Angustias Hematol Rep Case Report Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0–3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time. PAGEPress Publications 2011-10-10 /pmc/articles/PMC3238480/ /pubmed/22184537 http://dx.doi.org/10.4081/hr.2011.e16 Text en ©Copyright J.A. Morales-Molina, et al. 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy |
spellingShingle | Case Report Morales-Molina, José Antonio Martínez-de la Plata, Juan Enrique Urquízar-Rodríguez, Olivia Molina-Arrebola, María Angustias Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title | Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_full | Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_fullStr | Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_full_unstemmed | Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_short | Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_sort | bosentan and oral anticoagulants in hiv patients: what we can learn of cases reported so far |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238480/ https://www.ncbi.nlm.nih.gov/pubmed/22184537 http://dx.doi.org/10.4081/hr.2011.e16 |
work_keys_str_mv | AT moralesmolinajoseantonio bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT martinezdelaplatajuanenrique bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT urquizarrodriguezolivia bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT molinaarrebolamariaangustias bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar |